Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joanna Roder

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Cancer Immunology Research|December 7, 2017
A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic MelanomaJeffrey S Weber, Mario Sznol, Ryan J Sullivan, et al.
Cancers|September 9, 2020
Definition and Independent Validation of a Proteomic-Classifier in Ovarian CancerSabine Kasimir-Bauer, Joanna Roder, Eva Obermayr, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, et al.
Journal of Pancreatic Cancer|March 31, 2021
A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas CancerPeter Muscarella, Tanios Bekaii-Saab, Kristi McIntyre, et al.
The Lancet. Oncology|May 17, 2014
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trialVanesa Gregorc, Silvia Novello, Chiara Lazzari, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Cancer Immunology Research|December 7, 2017
A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic MelanomaJeffrey S Weber, Mario Sznol, Ryan J Sullivan, et al.
Cancers|September 9, 2020
Definition and Independent Validation of a Proteomic-Classifier in Ovarian CancerSabine Kasimir-Bauer, Joanna Roder, Eva Obermayr, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, et al.
Journal of Pancreatic Cancer|March 31, 2021
A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas CancerPeter Muscarella, Tanios Bekaii-Saab, Kristi McIntyre, et al.
The Lancet. Oncology|May 17, 2014
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trialVanesa Gregorc, Silvia Novello, Chiara Lazzari, et al.
Pageof 3